The invention relates to a simvastatin-gliclazide co-amorphous compound which is formed by combining simvastatin and gliclazide. An X-ray powder diffraction spectrum represented by the degree 2theta with Cu-K[alpha] irradiation has no sharp diffraction peak. An infrared absorption spectrum obtained by KBr pellet determination has absorption peaks at the points of 3461 3285 3018 2964 2871 1717 1598 1451 1391 1355 1312 1258 1164 1124 1056 991 862 670 548 and 531 cm. The DSC glass-transition temperature is 49.3 DEG C. The simvastatin-gliclazide co-amorphous compound and the physical mixture of the simvastatin and the gliclazide have different melting points powder X-ray diffraction DSC and infrared spectrums and therefore the solid state provided by the invention is an amorphous state completely different from the simvastatin crystal and the gliclazide crystal.

暂无附图